navtemadlin (KRT-232) / Kartos Therap 
Welcome,         Profile    Billing    Logout  
 7 Diseases   15 Trials   15 Trials   324 News 
22 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
navtemadlin (KRT-232) / Kartos Therap
POIESIS, NCT06479135: Study of Navtemadlin Add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib

Recruiting
3
600
Europe, US, RoW
Navtemadlin, KRT-232, Navtemadlin placebo, Ruxolitinib, Jakafi, Jakavi
Kartos Therapeutics, Inc.
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF
12/26
12/28
BOREAS, NCT03662126 / 2018-001671-21: KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment

Recruiting
2/3
385
Europe, Canada, US, RoW
KRT-232, Best Available Therapy (BAT)
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Post-Essential Thrombocythemia MF (Post-ET-MF)
12/23
12/25
ENGOT en-21, NCT05797831: Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

Recruiting
2/3
268
Europe, Canada, US, RoW
Navtemadlin, KRT-232, Navtemadlin Placebo
Kartos Therapeutics, Inc., European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
Endometrial Cancer
08/25
07/27
NCT03669965 / 2018-001672-38: KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Active, not recruiting
2a/2b
20
Europe, US
KRT-232, Ruxolitinib
Kartos Therapeutics, Inc.
Polycythemia Vera
04/22
10/22
2020-005642-42: Clinical Trial of 2 separate investigational products (KRT-232 and TL-895) to assess their safety and effectiveness in treating patients with Myelofibrosis.

Not yet recruiting
2
104
Europe, RoW
KRT-232, TL-895, KRT-232, TL-895, Tablet, Film-coated tablet
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary, post-polycythemia vera (PV), or post-essential thrombocythemia (ET) myelofibrosis (MF), who are treatment naïve to any JAK inhibitor., Myelofibrosis, Diseases [C] - Cancer [C04]
 
 
NCT05027867 / 2021-001530-19: KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Terminated
2
3
Europe, US, RoW
KRT-232, navtemadlin
Kartos Therapeutics, Inc.
Small-cell Lung Cancer, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage, Small Cell Lung Cancer Recurrent
08/22
08/22
NCT04878003 / 2020-005642-42: Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Recruiting
2
52
Europe, US, RoW
KRT-232, TL-895
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
05/24
10/25
KRT-232-113, NCT04640532 / 2020-002392-35: KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Recruiting
1b/2
116
Europe, US, RoW
KRT-232, TL-895
Kartos Therapeutics, Inc., Telios Pharma, Inc.
Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
05/22
07/25
NCT04485260 / 2019-004554-29: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Recruiting
1b/2
36
Europe, US, RoW
KRT-232, Ruxolitinib, Jakafi, Jakavi
Kartos Therapeutics, Inc.
Myelofibrosis
10/22
10/24
NCT04502394 / 2020-002464-31: Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Recruiting
1b/2
84
Europe, US, RoW
KRT-232, acalabrutinib, ACP-196
Kartos Therapeutics, Inc., Kartos Therapeutics, Inc.
Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma
10/22
03/24
NOTOS, NCT03787602 / 2020-002820-35: Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Recruiting
1b/2
115
Europe, Canada, US, RoW
KRT-232, navtemadlin, Avelumab, Bavencio
Kartos Therapeutics, Inc.
Merkel Cell Carcinoma
11/24
08/25
NCT04669067 / 2020-003109-73: TL-895 and KRT-232 Study in Acute Myeloid Leukemia

Active, not recruiting
1b/2
18
Europe, US, RoW
TL-895, KRT-232
Telios Pharma, Inc., Kartos Therapeutics, Inc.
Acute Myeloid Leukemia
11/24
11/25
KRT-232-117, NCT04835584 / 2020-004699-16: KRT-232 and TKI Study in Chronic Myeloid Leukemia

Recruiting
1b/2
109
Europe, Canada, US, RoW
KRT-232, Dasatinib, Dasatinib Zentiva, Nilotinib, Tasigna
Kartos Therapeutics, Inc.
Chronic Myeloid Leukemia
12/24
06/26
2020-002464-31: A study to evaluate the safety and efficacy of KRT-232 in combination with Acalabrutinib in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia. Vizsgálat az acalabrutinibbel együtt adott KRT-232 biztonságosságának és hatásosságának értékelésére relapszált/refrakter diffúz nagy B-sejtes limfómában vagy relapszált/refrakter krónikus limfocitás leukémiában szenvedő betegeknél

Not yet recruiting
1/2
114
Europe, RoW
Acalabrutinib, KRT-232, Tablet, Capsule, hard, CALQUENCE
Kartos Therapeutics Inc., Kartos Therapeutics, Inc, Kartos Therapeutics, Inc.
- Relapsed/Refractory (R/R) de novo TP53 ABC (non-GCB) or GCB diffuse large B-cell lymphoma (DLBCL)- R/R TP53 chronic lymphocytic leukemia (CLL) naïve to prior Bruton's tyrosine kinase (BTK) inhibitor- R/R DLBCL with non-germinal center B-cell like(GCB) subtype- R/R DLBCL with double-expressor lymphoma subtype, - Relapsed/Refractory Diffuse Large B-cell Lymphoma- Relapsed/Refractory Chronic Lymphocytic Leukemia, Diseases [C] - Cancer [C04]
 
 
NCT04113616 / 2019-001201-24: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Terminated
1/2
70
Europe, US, RoW
KRT-232, Cytarabine, cytosine arabinoside, Cytosar-U, Depocyt, Arabinosylcytosine, Ara-C, Decitabine, Dacogen
Kartos Therapeutics, Inc.
Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)
09/23
09/23
MS200662_0001, NCT02825836 / 2016-000286-23: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

Active, not recruiting
1/2
130
Europe, US, RoW
TL-895, Navtemadlin
Telios Pharma, Inc.
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
12/24
12/25
NCT05705466: Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Withdrawn
1/2
92
NA
Navtemadlin, KRT-232, Navtemadlin Placebo, Pembrolizumab, Keytruda
Kartos Therapeutics, Inc.
Non Small Cell Lung Cancer
06/25
06/27
NCT03041688: Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

Active, not recruiting
1
58
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Decitabine, 5-Aza-2'-deoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Venetoclax, ABT 199, ABT-0199, ABT-199, ABT199, GDC 0199, GDC-0199, GDC0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
06/26
06/26
NCT03031730: Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Terminated
1
35
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Carfilnat, CFZ, Kyprolis, PR 171, PR-171, PR171, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, LenaDex, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Dexamethasone Sodium Phosphate, Cebedex, Corson, Dalalone, Decaject, Dekasol LA, Dexacen, Dexamethasone Sodium Phosphates, Dexasone, Dezone, ReadySharp Dexamethasone, Soludecadron, Solurex, Topidex, Echocardiography, EC, Lenalidomide, CC 5013, CC-5013, CC5013, CDC 501, Revlimid, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232
National Cancer Institute (NCI)
Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
07/24
07/24
NRG-DT001, NCT03217266: Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma

Active, not recruiting
1
39
US
Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery
National Cancer Institute (NCI), NRG Oncology
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
08/23
02/25
ALLIANCE-ABTC-1604, NCT03107780: Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer

Suspended
1
86
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma, MGMT-Unmethylated Glioblastoma, Recurrent Glioblastoma
12/24
12/24
NCT04190550: Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia

Active, not recruiting
1
24
US
Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Idarubicin Hydrochloride, Idamycin, Idamycin PFS, Idarubicin HCl, IMI-30, SC-33428, Zavedos, Navtemadlin, (3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid, AMG 232, AMG-232, KRT 232, KRT-232, KRT232, MDM2 Inhibitor KRT-232
National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
06/25
06/25

Download Options